- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01282814
Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study
February 11, 2011 updated by: Teva Pharmaceuticals USA
Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as the Content of 1 x 150 mg Extended-Release Capsule Mixed With Applesauce in Healthy Subjects Under Fasting Conditions.
The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg capsules (test) versus Effexor® XR (reference) administered as the content of 1 x 150 mg extended-release capsule mixed with applesauce under fasting conditions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Sainte-Foy, Quebec, Canada, G1V 2K8
- Anapharm Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Members of the community at large.
- Subjects will be females and/or males, non-smokers, 18 years of age and older.
- Female subjects will be postmenopausal or surgically sterilized.
Exclusion Criteria:
- Clinically significant illness within 4 weeks of the administration of study medication.
- Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- Any clinically significant abnormality found during medical screening.
- Any reason which, in the opinion of the medical sub-investigator, would prevent the subject from participating in the study.
- Abnormal laboratory tests judged clinically significant.
- Positive urine drug screen at screening.
- Positive testing for hepatitis B, hepatitis C, or HIV at screening.
- ECG abnormalities (clinically significant) or vital sign abnormalities at screening.
- Subjects with BMI greater than 30.0.
- History of significant alcohol abuse within 6 months of the screening visit or any indication of the regular use of more than 14 units of alcohol per week (1 unit is equal to 150 mL of wine, 360mL of beer, or 45 mL of alcohol 40%).
- History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, PCP, crack) within 1 year of the screening visit.
- History of allergic reactions to venlafaxine.
- History of allergic reactions to heparin.
- Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication.
- Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
- History or presence of any clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
- Any history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or metabolic disease.
- Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication, except for topical products without systemic exposure.
- Positive alcohol breath test at screening.
- Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
- Any food allergies, intolerance, restriction, or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
- Subjects who have had a depot injection or implant of any drug 3 months prior to administration of study medication.
Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to administration of the study medication as follows:
- less than 300 mL of whole blood within 30 days or
- 300 mL to 500 mL of whole blood within 45 days or
- more than 500 mL of whole blood within 56 days.
- Subjects who have consumed food or beverages containing grapefruit within 7 days prior to administration of the study medication.
- Subjects with clinically significant presence or history of raised intra-ocular pressure or at the risk of acute narrow angle glaucoma.
- Subjects who have dentures or braces.
- Intolerance to venipunctures.
- Subjects with a clinically significant history of tuberculosis, epilepsy, asthma, diabetes, or psychosis will not be eligible for this study.
- Subjects who are unable to understand or unwilling to sign the Informed Consent Form.
- Subjects with the known presence of volume-depletion.
- Subjects predisposed to bleeding of the skin and mucous membrane (impaired platelet aggregation).
- Subjects with clinically significant history of seizures.
Additional exclusion criteria for females only:
- Breastfeeding subjects.
- Positive urine pregnancy test screen at screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Reference Listed Drug
Effexor® XR 150 mg Extended-Release Capsules
|
150 mg Extended-Release Capsule
Other Names:
|
Experimental: Investigational Test Product
Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
|
150 mg Extended-Release Capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of Venlafaxine.
Time Frame: Blood samples collected over a 48 hour period.
|
Bioequivalence based on Venlafaxine Cmax (maximum observed concentration of drug substance in plasma).
|
Blood samples collected over a 48 hour period.
|
AUC0-t of Venlafaxine.
Time Frame: Blood samples collected over a 48 hour period.
|
Bioequivalence based on Venlafaxine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
|
Blood samples collected over a 48 hour period.
|
AUC0-inf of Venlafaxine.
Time Frame: Blood samples collected over a 48 hour period.
|
Bioequivalence based on Venlafaxine AUC0-inf (area under the concentration-time curve from time zero to infinity).
|
Blood samples collected over a 48 hour period.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2003
Primary Completion (Actual)
March 1, 2003
Study Completion (Actual)
March 1, 2003
Study Registration Dates
First Submitted
January 24, 2011
First Submitted That Met QC Criteria
January 24, 2011
First Posted (Estimate)
January 25, 2011
Study Record Updates
Last Update Posted (Estimate)
March 8, 2011
Last Update Submitted That Met QC Criteria
February 11, 2011
Last Verified
February 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Serotonin and Noradrenaline Reuptake Inhibitors
- Venlafaxine Hydrochloride
Other Study ID Numbers
- 30024
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Venlafaxine Hydrochloride
-
ShireCompletedHealthyUnited States
-
Xijing HospitalUnknown
-
Actavis Inc.Completed
-
First Affiliated Hospital of Zhejiang UniversityNot yet recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.UnknownMajor Depressive DisorderChina
-
Guangzhou General Hospital of Guangzhou Military...CompletedIschemic Stroke | Subcortical AphasiaChina
-
Teva Pharmaceuticals USACompleted
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaCompletedSleeve Gastrectomy | Roux en Y Gastric BypassUnited States
-
Torrent Pharmaceuticals LimitedCompleted
-
University of California, Los AngelesWyeth is now a wholly owned subsidiary of PfizerCompleted